Midori Morita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Midori Morita has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Koichi Sakaguchi
Department of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
11 shared publications - Yasuto Naoi
Kyoto Prefectural University of Medicine: Kyoto Furitsu Ika Daigaku
8 shared publications - Chikage Kato
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
7 shared publications - Akira Watanabe
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
6 shared publications - Sae Kitano
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
6 shared publications - Yoshiaki Sota
Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
5 shared publications
Latest Publications
- 20 May 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (4) , 841-852
Comparative evaluation of treatment recommendations generated by generative AI and breast cancer specialists for advanced and recurrent breast cancer: a multidimensional assessment of evidence interpretation and clinical decision support
Background Large language models (LLMs), a form of generative artificial intelligence (AI), are increasingly explored for clinical applications due to their ability to synthesize medical information. In breast cancer care, where therapeutic decision-making is complex because of expanding treatment options, AI-based decision support tools may improve efficiency and consistency. However, their clinical validity and safety remain insufficiently evaluated in real-world settings. The present study aimed to compare the characteristics of treatment recommendations generated by a large language model with those proposed by breast cancer specialists using identical clinical information. Methods This retrospective observational study included 100 patients with advanced or recurrent breast cancer. Clinical information was provided to ChatGPT using a standardized prompt to generate treatment recommendations. Six board-certified breast cancer specialists independently proposed treatment strategies for the same cases. Recommendations were evaluated using five predefined criteria: 1. Comprehensiveness and appropriateness of literature selection, 2. Accuracy of interpretation of key evidence, 3. Clinical appropriateness and diversity of treatment options, 4. Accuracy of adverse event information, 5. Time required to generate recommendations. Group comparisons were performed using linear mixed-effects models with case and evaluator as random effects. Results ChatGPT achieved higher scores than specialists across all five evaluation criteria, with the largest difference observed for accuracy of key evidence interpretation. The mean total score was 93.7 for ChatGPT and 44.1 for specialists, and linear mixed-effects model analysis confirmed a significantly higher total score for ChatGPT (p < 0.001). These findings suggest that AI-generated responses tended to provide more comprehensive and structured summaries of available evidence within the predefined evaluation framework. Conclusions LLMs were able to generate comprehensive and structured treatment recommendations based on the provided clinical information. However, these findings primarily reflect differences in information synthesis under predefined evaluation criteria rather than superiority in real-world clinical decision-making. Given the potential risk of hallucinations, AI should be positioned as an assistive tool to support specialist-led decision-making in breast cancer care.
- 20 May 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (4) , 841-852
Comparative evaluation of treatment recommendations generated by generative AI and breast cancer specialists for advanced and recurrent breast cancer: a multidimensional assessment of evidence interpretation and clinical decision support
Background Large language models (LLMs), a form of generative artificial intelligence (AI), are increasingly explored for clinical applications due to their ability to synthesize medical information. In breast cancer care, where therapeutic decision-making is complex because of expanding treatment options, AI-based decision support tools may improve efficiency and consistency. However, their clinical validity and safety remain insufficiently evaluated in real-world settings. The present study aimed to compare the characteristics of treatment recommendations generated by a large language model with those proposed by breast cancer specialists using identical clinical information. Methods This retrospective observational study included 100 patients with advanced or recurrent breast cancer. Clinical information was provided to ChatGPT using a standardized prompt to generate treatment recommendations. Six board-certified breast cancer specialists independently proposed treatment strategies for the same cases. Recommendations were evaluated using five predefined criteria: 1. Comprehensiveness and appropriateness of literature selection, 2. Accuracy of interpretation of key evidence, 3. Clinical appropriateness and diversity of treatment options, 4. Accuracy of adverse event information, 5. Time required to generate recommendations. Group comparisons were performed using linear mixed-effects models with case and evaluator as random effects. Results ChatGPT achieved higher scores than specialists across all five evaluation criteria, with the largest difference observed for accuracy of key evidence interpretation. The mean total score was 93.7 for ChatGPT and 44.1 for specialists, and linear mixed-effects model analysis confirmed a significantly higher total score for ChatGPT (p < 0.001). These findings suggest that AI-generated responses tended to provide more comprehensive and structured summaries of available evidence within the predefined evaluation framework. Conclusions LLMs were able to generate comprehensive and structured treatment recommendations based on the provided clinical information. However, these findings primarily reflect differences in information synthesis under predefined evaluation criteria rather than superiority in real-world clinical decision-making. Given the potential risk of hallucinations, AI should be positioned as an assistive tool to support specialist-led decision-making in breast cancer care.
- Open Access
- 21 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3704
Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer
Endocrine therapy is the mainstay for estrogen receptor (ER) α-positive breast cancer (BC), yet many patients display acquired resistance. We then screened natural compounds using human ERα-positive BC cells and identified perillyl alcohol (POH), a monoterpene from perilla, that reduces ERα protein levels. Chemoproteome analysis using POH-immobilized nanomagnetic beads revealed adenine nucleotide translocase 2 (ANT2), a mitochondrial inner membrane protein, as a direct target of POH. Molecular dynamics (MD) simulations predicted POH binding to the central pore of ANT2, which functions in ATP transport. ANT2 depletion reduced ERα levels, and public datasets indicate that high ANT2 expression correlates with poor prognosis in ERα-positive BC. POH also inhibited the growth of Tamoxifen- and Fulvestrant-resistant BC cells. RNA sequencing showed that fatty acid elongation-related genes were upregulated in Fulvestrant-resistant cells but downregulated by ANT2 depletion. Both ANT2 depletion and POH treatment led to the accumulation of intracellular lipid droplets in Fulvestrant-resistant cells, consistent with impaired fatty acid elongation. Finally, in silico screening using MD simulations identified venetoclax and nystatin as potential ANT2 pore binders. Both compounds reduced ERα levels in ERα-positive BC cells and increased lipid droplet formation in Fulvestrant-resistant cells. These findings highlight ANT2 as a druggable target against endocrine-resistant BC.
- 21 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3704
Open AccessIdentification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer
Endocrine therapy is the mainstay for estrogen receptor (ER) α-positive breast cancer (BC), yet many patients display acquired resistance. We then screened natural compounds using human ERα-positive BC cells and identified perillyl alcohol (POH), a monoterpene from perilla, that reduces ERα protein levels. Chemoproteome analysis using POH-immobilized nanomagnetic beads revealed adenine nucleotide translocase 2 (ANT2), a mitochondrial inner membrane protein, as a direct target of POH. Molecular dynamics (MD) simulations predicted POH binding to the central pore of ANT2, which functions in ATP transport. ANT2 depletion reduced ERα levels, and public datasets indicate that high ANT2 expression correlates with poor prognosis in ERα-positive BC. POH also inhibited the growth of Tamoxifen- and Fulvestrant-resistant BC cells. RNA sequencing showed that fatty acid elongation-related genes were upregulated in Fulvestrant-resistant cells but downregulated by ANT2 depletion. Both ANT2 depletion and POH treatment led to the accumulation of intracellular lipid droplets in Fulvestrant-resistant cells, consistent with impaired fatty acid elongation. Finally, in silico screening using MD simulations identified venetoclax and nystatin as potential ANT2 pore binders. Both compounds reduced ERα levels in ERα-positive BC cells and increased lipid droplet formation in Fulvestrant-resistant cells. These findings highlight ANT2 as a druggable target against endocrine-resistant BC.
- Open Access
- 3 April 2026
- Published by Springer Nature in Research Square
Real-World Landscape of Genomic Medicine in Breast Cancer Revealed by the C-CAT Database: Reappraisal of Drug Accessibility and Clinical Utility in 6,307 Patients
Background Comprehensive genomic profiling (CGP) has advanced precision oncology in breast cancer, yet its real-world contribution to treatment selection in Japan remains unclear. Methods We analyzed 6,307 Japanese patients with breast cancer who underwent CGP in the nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. Drug accessibility to Pharmaceuticals and Medical Devices Agency (PMDA)-approved therapies was assessed using two criteria, excluding biomarkers identifiable by prior companion diagnostics: Criterion I reflecting phase III breast cancer trials, and Criterion II reflecting phase I/II basket or tumor-agnostic trials. Evidence levels at testing were compared with those reassessed using evidence available as of October 2025. Results At least one genomic alteration was detected in 97.6% of cases; TP53 (53.9%), PIK3CA (37.7%) were most frequent. Re-evaluation increased Evidence Level A assignments from 3,757 to 5,874. Nevertheless, biomarkers linked to PMDA-approved therapies were limited to ten categories: PIK3CA/AKT1/PTEN alterations, ERBB2 amplification, BRCA1/2 mutations, NTRK fusions, BRAF V600 mutation, and TMB-H/MSI-H. Drug accessibility was 30.8% under Criterion I, driven exclusively by eligibility for capivasertib. Under Criterion II, the accessibility was 19.5%, comprising ERBB2 amplification (4.7%), somatic BRCA1/2 mutations (3.4%), NTRK fusions (0.1%), BRAF V600 mutation (0.2%), and non-overlapping TMB-H/MSI-H (11.1%). The prevalence of somatic BRCA1/2 mutations in germline BRCA1/2 noncarriers were identified in 3.4%, representing the first large-scale estimate in Japanese breast cancer. Conclusion Despite high detection rates, translation into PMDA-approved therapies remains limited, underscoring the need to optimize testing timing, expand trial access, harmonize molecular tumor boards practice, and consider breast cancer–specific mini-panels.
- 3 April 2026
- Published by Springer Nature in Research Square
Open AccessReal-World Landscape of Genomic Medicine in Breast Cancer Revealed by the C-CAT Database: Reappraisal of Drug Accessibility and Clinical Utility in 6,307 Patients
Background Comprehensive genomic profiling (CGP) has advanced precision oncology in breast cancer, yet its real-world contribution to treatment selection in Japan remains unclear. Methods We analyzed 6,307 Japanese patients with breast cancer who underwent CGP in the nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. Drug accessibility to Pharmaceuticals and Medical Devices Agency (PMDA)-approved therapies was assessed using two criteria, excluding biomarkers identifiable by prior companion diagnostics: Criterion I reflecting phase III breast cancer trials, and Criterion II reflecting phase I/II basket or tumor-agnostic trials. Evidence levels at testing were compared with those reassessed using evidence available as of October 2025. Results At least one genomic alteration was detected in 97.6% of cases; TP53 (53.9%), PIK3CA (37.7%) were most frequent. Re-evaluation increased Evidence Level A assignments from 3,757 to 5,874. Nevertheless, biomarkers linked to PMDA-approved therapies were limited to ten categories: PIK3CA/AKT1/PTEN alterations, ERBB2 amplification, BRCA1/2 mutations, NTRK fusions, BRAF V600 mutation, and TMB-H/MSI-H. Drug accessibility was 30.8% under Criterion I, driven exclusively by eligibility for capivasertib. Under Criterion II, the accessibility was 19.5%, comprising ERBB2 amplification (4.7%), somatic BRCA1/2 mutations (3.4%), NTRK fusions (0.1%), BRAF V600 mutation (0.2%), and non-overlapping TMB-H/MSI-H (11.1%). The prevalence of somatic BRCA1/2 mutations in germline BRCA1/2 noncarriers were identified in 3.4%, representing the first large-scale estimate in Japanese breast cancer. Conclusion Despite high detection rates, translation into PMDA-approved therapies remains limited, underscoring the need to optimize testing timing, expand trial access, harmonize molecular tumor boards practice, and consider breast cancer–specific mini-panels.
- 25 September 2025
- Published by Springer Nature in Breast Cancer
- Vol. 33 (1) , 99-110
Pathological homogeneity and utility in the genetic diagnosis of paired mirror samples from breast cancer 10G-vacuum-assisted biopsies using a novel longitudinal dividing device
Background The growing need for immunohistochemical and genetic testing often results in shortage of breast cancer vacuum-assisted biopsy (VAB) samples. Their value has become increasingly important with improvements in neoadjuvant chemotherapy outcomes. To enhance diagnostic utility, the longitudinal division of a single VAB sample can provide matched “mirror samples.” We adapted a prostate biopsy tissue divider for use with 10G-VAB breast cancer specimens and evaluated its feasibility for pathological and molecular analyses. Methods A total of 100 10G-VAB specimens from 32 patients were longitudinally bisected using the dividing tool. The pathological concordance between the paired mirror samples was assessed by histological examination. Their suitability for DNA and mRNA analyses was also evaluated by next-generation gene panel sequencing and microarray-based gene expression profiling. Results Of the 72 samples confirmed to contain malignant tissue, 70 (97.2%) exhibited high pathological concordance between the mirror pairs. The remaining two samples (2.8%), derived from the tumor margins, exhibited discordant histological findings. Moreover, gene panel testing (n = 8) and comprehensive gene expression profiling using microarray (n = 8) were successfully performed on all of the mirror samples (n = 16). Conclusion The longitudinal division of breast cancer VAB tissue using a specialized dividing device results in anatomically matched mirror samples with high pathological fidelity. These specimens are suitable for advanced molecular diagnostics, thus providing a valuable tool for clinical practice and translational studies.
- 25 September 2025
- Published by Springer Nature in Breast Cancer
- Vol. 33 (1) , 99-110
Pathological homogeneity and utility in the genetic diagnosis of paired mirror samples from breast cancer 10G-vacuum-assisted biopsies using a novel longitudinal dividing device
Background The growing need for immunohistochemical and genetic testing often results in shortage of breast cancer vacuum-assisted biopsy (VAB) samples. Their value has become increasingly important with improvements in neoadjuvant chemotherapy outcomes. To enhance diagnostic utility, the longitudinal division of a single VAB sample can provide matched “mirror samples.” We adapted a prostate biopsy tissue divider for use with 10G-VAB breast cancer specimens and evaluated its feasibility for pathological and molecular analyses. Methods A total of 100 10G-VAB specimens from 32 patients were longitudinally bisected using the dividing tool. The pathological concordance between the paired mirror samples was assessed by histological examination. Their suitability for DNA and mRNA analyses was also evaluated by next-generation gene panel sequencing and microarray-based gene expression profiling. Results Of the 72 samples confirmed to contain malignant tissue, 70 (97.2%) exhibited high pathological concordance between the mirror pairs. The remaining two samples (2.8%), derived from the tumor margins, exhibited discordant histological findings. Moreover, gene panel testing (n = 8) and comprehensive gene expression profiling using microarray (n = 8) were successfully performed on all of the mirror samples (n = 16). Conclusion The longitudinal division of breast cancer VAB tissue using a specialized dividing device results in anatomically matched mirror samples with high pathological fidelity. These specimens are suitable for advanced molecular diagnostics, thus providing a valuable tool for clinical practice and translational studies.
- 25 June 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (5) , 1075-1087
Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies
Background In recent years, multigene assays have become indispensable tools for predicting the recurrence risk of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and guiding adjuvant chemotherapy decisions. Curebest™ 95GC Breast (95GC), developed in 2011 as a domestically produced multigene assay for postoperative recurrence prediction, has been commercially available since 2013. Since 2021, five validation studies evaluating the predictive performance 95GC have been published. This study presents an integrated analysis of these studies to validate the prognostic utility of 95GC further. Methods The integrated analysis included 719 real-world cases of luminal-type node-negative breast cancer patients who underwent adjuvant hormone therapy alone without extended endocrine treatment. In addition, an expanded cohort incorporating 294 cases from Western patients within the GEO public database was analyzed, resulting in a total of 1013 cases. Results Among the 719 real-world cases, 550 (76.5%) were classified into the 95GC Low-risk group, demonstrating a significantly superior prognosis compared to the High-risk group (P < 1.00e−12). The 5-year distant recurrence-free survival (DRFS) rate in the Low-risk group was approximately 98%, with consistent findings observed in the expanded cohort. Furthermore, an analysis of 754 CEL files using 21GC (a proxy for Oncotype DX®) identified 318 cases (42.2%) as the 21GC intermediate risk. 95GC successfully stratified these cases into two prognostically distinct subgroups. Conclusions These findings underscore the clinical utility of 95GC in safely omitting chemotherapy for Low-risk patients with good prognosis and in further stratifying the 21GC Intermediate-risk cases, thereby contributing to personalized treatment strategies.
- 25 June 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (5) , 1075-1087
Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies
Background In recent years, multigene assays have become indispensable tools for predicting the recurrence risk of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and guiding adjuvant chemotherapy decisions. Curebest™ 95GC Breast (95GC), developed in 2011 as a domestically produced multigene assay for postoperative recurrence prediction, has been commercially available since 2013. Since 2021, five validation studies evaluating the predictive performance 95GC have been published. This study presents an integrated analysis of these studies to validate the prognostic utility of 95GC further. Methods The integrated analysis included 719 real-world cases of luminal-type node-negative breast cancer patients who underwent adjuvant hormone therapy alone without extended endocrine treatment. In addition, an expanded cohort incorporating 294 cases from Western patients within the GEO public database was analyzed, resulting in a total of 1013 cases. Results Among the 719 real-world cases, 550 (76.5%) were classified into the 95GC Low-risk group, demonstrating a significantly superior prognosis compared to the High-risk group (P < 1.00e−12). The 5-year distant recurrence-free survival (DRFS) rate in the Low-risk group was approximately 98%, with consistent findings observed in the expanded cohort. Furthermore, an analysis of 754 CEL files using 21GC (a proxy for Oncotype DX®) identified 318 cases (42.2%) as the 21GC intermediate risk. 95GC successfully stratified these cases into two prognostically distinct subgroups. Conclusions These findings underscore the clinical utility of 95GC in safely omitting chemotherapy for Low-risk patients with good prognosis and in further stratifying the 21GC Intermediate-risk cases, thereby contributing to personalized treatment strategies.
- 11 June 2024
- Published by Springer Nature in Breast Cancer
- Vol. 31 (5) , 898-908
Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer
Background The mechanism of late recurrence (LR) of estrogen receptor (ER)-positive breast cancer remains unclear, as previous studies have separately investigated “gene expression profiles” and “clinicopathological factors.” Thus, this study aimed to evaluate the predictive capability of LR by combining the two independent factors of gene expression profiles (42-gene classifier: 42GC) and clinicopathological factors (Clinical Treatment Score post-5 years: CTS5) in multiple large cohorts. Methods We analyzed microarray CEL file data downloaded from public databases of 28 global cohorts. A total of 2,454 patients with ER-positive breast cancer were analyzed for 42GC, and 1,263 of these, with complete clinicopathological data were analyzed for CTS5. Results In the analysis of recurrent patients, the 42GC LR and CTS5 low-risk group tended to have LR. Notably, in the analysis of patients with and without recurrence, the highest LR rate beyond 5 years was observed in the CTS5 high-risk group. The combination of the 42GC and CTS5 high-risk groups showed the highest LR rate (16.9%), significantly exceeding that of the 42GC non-LR (NLR) and CTS5 low-risk combination (5.41%) (p = 0.038, odds ratio = 3.53). Furthermore, incorporating a third factor, 95GC, potentially reduced the number of patients prioritized for extended hormonal therapy for approximately one-quarter of patients. Conclusions Results confirmed that the two factors, gene expression profiles and clinicopathological factors, affect the time of recurrence. It also showed that the biological predisposition for LR (CTS5 low-risk) differed from the high LR rate (CTS5 high-risk). In clinical practice, patients with the 42GC LR and CTS5 high-risk combination should be prioritized for extended hormonal therapy. The addition of CTS5 and 95GC to 42GC allows for better risk classification of LR.
- 11 June 2024
- Published by Springer Nature in Breast Cancer
- Vol. 31 (5) , 898-908
Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer
Background The mechanism of late recurrence (LR) of estrogen receptor (ER)-positive breast cancer remains unclear, as previous studies have separately investigated “gene expression profiles” and “clinicopathological factors.” Thus, this study aimed to evaluate the predictive capability of LR by combining the two independent factors of gene expression profiles (42-gene classifier: 42GC) and clinicopathological factors (Clinical Treatment Score post-5 years: CTS5) in multiple large cohorts. Methods We analyzed microarray CEL file data downloaded from public databases of 28 global cohorts. A total of 2,454 patients with ER-positive breast cancer were analyzed for 42GC, and 1,263 of these, with complete clinicopathological data were analyzed for CTS5. Results In the analysis of recurrent patients, the 42GC LR and CTS5 low-risk group tended to have LR. Notably, in the analysis of patients with and without recurrence, the highest LR rate beyond 5 years was observed in the CTS5 high-risk group. The combination of the 42GC and CTS5 high-risk groups showed the highest LR rate (16.9%), significantly exceeding that of the 42GC non-LR (NLR) and CTS5 low-risk combination (5.41%) (p = 0.038, odds ratio = 3.53). Furthermore, incorporating a third factor, 95GC, potentially reduced the number of patients prioritized for extended hormonal therapy for approximately one-quarter of patients. Conclusions Results confirmed that the two factors, gene expression profiles and clinicopathological factors, affect the time of recurrence. It also showed that the biological predisposition for LR (CTS5 low-risk) differed from the high LR rate (CTS5 high-risk). In clinical practice, patients with the 42GC LR and CTS5 high-risk combination should be prioritized for extended hormonal therapy. The addition of CTS5 and 95GC to 42GC allows for better risk classification of LR.
- 8 April 2024
- Published by Springer Nature in Breast Cancer
- Vol. 31 (4) , 593-606
Investigation of recurrence prediction ability of EndoPredict® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict® from microarray data from fresh-frozen to FFPE tissues
Background EndoPredict® (EP) is a multigene assay to predict distant recurrence risk in luminal breast cancer. EP measures the expression of 12 genes in primary tumor by qRT-PCR from formalin-fixed paraffin-embedded (FFPE) tissues and calculates EP risk score that indicates the risk of distant recurrence. We evaluated the performance of EP in predicting distant recurrence risk using microarray data from fresh frozen (FF) tissues. We also examined the applicability of EP to microarray data from FFPE tissues. Methods We analyzed the publicly available data of 431 node-negative and 270 node-positive patients with luminal breast cancer who received endocrine therapy alone. We evaluated the prognostic value of EP using microarray data from FF tissues. Next, we created an algorithm to calculate EP risk score using microarray data from FFPE tissues. We examined the correlation coefficient of EP risk score and concordance rate of EP risk high/low using microarray data from FFPE/FF tissue pairs in a validation set of 39 patients. Results In 431 node-negative patients, the distant recurrence-free survival (DRFS) rate was significantly worse in those with high EP risk scores (P = 3.68 × 10−6, log-rank). The 5-year DRFS was 95.2% in those with low EP risk score. In the validation set, the correlation coefficient of EP risk score was 0.93 and the concordance rate of EP risk high/low was 91.7%. Conclusions EP using microarray data from FF tissues was useful in predicting distant recurrence risk in luminal breast cancer, and EP might be utilized in microarray data from FFPE tissues.
- 8 April 2024
- Published by Springer Nature in Breast Cancer
- Vol. 31 (4) , 593-606
Investigation of recurrence prediction ability of EndoPredict® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict® from microarray data from fresh-frozen to FFPE tissues
Background EndoPredict® (EP) is a multigene assay to predict distant recurrence risk in luminal breast cancer. EP measures the expression of 12 genes in primary tumor by qRT-PCR from formalin-fixed paraffin-embedded (FFPE) tissues and calculates EP risk score that indicates the risk of distant recurrence. We evaluated the performance of EP in predicting distant recurrence risk using microarray data from fresh frozen (FF) tissues. We also examined the applicability of EP to microarray data from FFPE tissues. Methods We analyzed the publicly available data of 431 node-negative and 270 node-positive patients with luminal breast cancer who received endocrine therapy alone. We evaluated the prognostic value of EP using microarray data from FF tissues. Next, we created an algorithm to calculate EP risk score using microarray data from FFPE tissues. We examined the correlation coefficient of EP risk score and concordance rate of EP risk high/low using microarray data from FFPE/FF tissue pairs in a validation set of 39 patients. Results In 431 node-negative patients, the distant recurrence-free survival (DRFS) rate was significantly worse in those with high EP risk scores (P = 3.68 × 10−6, log-rank). The 5-year DRFS was 95.2% in those with low EP risk score. In the validation set, the correlation coefficient of EP risk score was 0.93 and the concordance rate of EP risk high/low was 91.7%. Conclusions EP using microarray data from FF tissues was useful in predicting distant recurrence risk in luminal breast cancer, and EP might be utilized in microarray data from FFPE tissues.
- Open Access
- 2 December 2023
- Published by Wiley in Cancer Science
- Vol. 115 (2) , 611-622
Seven‐plus hours of daily sedentary time and the subsequent risk of breast cancer: Japan Multi‐Institutional Collaborative Cohort Study
This study aimed to investigate the association between daily sedentary time and the risk of breast cancer (BC) in a large Japanese population. The participants were 36,023 women aged 35–69 years from the Japan Multi‐Institutional Collaborative Cohort Study. Cox proportional hazards analysis was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for BC incidence in relation to time spent sedentarily (categorical variables: <7 and ≥7 hours/day [h/d]). Additionally, the associations of BC incidence to the joint effect of sedentary time with each component of physical activity, such as leisure‐time metabolic equivalents (METs), frequency of leisure‐time physical activity, and daily walking time, were examined. During 315,189 person‐years of follow‐up, 554 incident cases of BC were identified. When compared to participants who spent <7 h/d sedentary, those who spent ≥7 h/d sedentary have a significantly higher risk of BC (HR, 1.36; 95% CI, 1.07–1.71). The corresponding HRs among participants who spent ≥7 h/d sedentary with more physical activity, such as ≥1 h/d for leisure‐time METs, ≥3 days/week of leisure‐time physical activity, and ≥1 h/d of daily walking were 1.58 (95% CI, 1.11–2.25), 1.77 (95% CI, 1.20–2.61), and 1.42 (95% CI, 1.10–1.83), respectively, compared with those who spent <7 h/d sedentary. This study found that spending ≥7 h/d of sedentary time is associated with the risk of BC. Neither leisure‐time physical activity nor walking had a BC‐preventive effect in those with ≥7 h/d of sedentary time.
- 2 December 2023
- Published by Wiley in Cancer Science
- Vol. 115 (2) , 611-622
Open AccessSeven‐plus hours of daily sedentary time and the subsequent risk of breast cancer: Japan Multi‐Institutional Collaborative Cohort Study
This study aimed to investigate the association between daily sedentary time and the risk of breast cancer (BC) in a large Japanese population. The participants were 36,023 women aged 35–69 years from the Japan Multi‐Institutional Collaborative Cohort Study. Cox proportional hazards analysis was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for BC incidence in relation to time spent sedentarily (categorical variables: <7 and ≥7 hours/day [h/d]). Additionally, the associations of BC incidence to the joint effect of sedentary time with each component of physical activity, such as leisure‐time metabolic equivalents (METs), frequency of leisure‐time physical activity, and daily walking time, were examined. During 315,189 person‐years of follow‐up, 554 incident cases of BC were identified. When compared to participants who spent <7 h/d sedentary, those who spent ≥7 h/d sedentary have a significantly higher risk of BC (HR, 1.36; 95% CI, 1.07–1.71). The corresponding HRs among participants who spent ≥7 h/d sedentary with more physical activity, such as ≥1 h/d for leisure‐time METs, ≥3 days/week of leisure‐time physical activity, and ≥1 h/d of daily walking were 1.58 (95% CI, 1.11–2.25), 1.77 (95% CI, 1.20–2.61), and 1.42 (95% CI, 1.10–1.83), respectively, compared with those who spent <7 h/d sedentary. This study found that spending ≥7 h/d of sedentary time is associated with the risk of BC. Neither leisure‐time physical activity nor walking had a BC‐preventive effect in those with ≥7 h/d of sedentary time.
- Open Access
- 24 July 2023
- Published by Springer Nature in Breast Cancer
- Vol. 30 (6) , 943-951
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve the prognosis of hormone receptor-positive HER2-negative advanced/metastatic breast cancer (HR+/HER2− mBC). However, some cancers show resistance to CDK4/6i and have a poor prognosis. The non-luminal disease score (NOLUS) was developed to predict non-luminal disease using immunohistochemical analysis. Methods: The association between the efficacy of CDK4/6i and NOLUS was investigated by evaluating pathological and clinical data, including real-world progression-free survival (rw-PFS) and overall survival (OS). Real-world data of patients with HR+/HER2− mBC who received CDK4/6i therapy [palbociclib or abemaciclib] as first- or second-line endocrine treatments was obtained. NOLUS was calculated using the formula: NOLUS (0–100) = − 0.45 × estrogen receptor (ER) (%) − 0.28 × progesterone receptor (PR) (%) + 0.27 × Ki67(%) + 73, and the patients were divided into two groups: NOLUS-positive (≥ 51.38) and NOLUS-negative (< 51.38). Results: Of the 300 patients, 28 (9.3%) were NOLUS-positive, and 272 (90.7%) were NOLUS-negative. The expression rates (%) of ER and PgR in NOLUS-positive patients were lower than those in NOLUS-negative patients (p < 0.001). Ki67 expression was higher in NOLUS-positive patients. There were statistically significant differences in prognosis (rw-PFS and OS) between the two groups. Moreover, NOLUS-negative patients showed statistically better rw-PFS with first-line therapy than second-line therapy. However, NOLUS-positive patients showed poor prognoses with both the first and second therapeutic lines, suggesting CDK4/6i inefficacy for NOLUS-positive patients. Conclusions: The efficacy and prognosis of CDK4/6i significantly differed between the NOLUS-positive and NOLUS-negative patients. This feasible method can predict patients with HR+/HER2− mBC resistant to CDK4/6i and help select a better therapeutic approach to overcome resistance.
- 24 July 2023
- Published by Springer Nature in Breast Cancer
- Vol. 30 (6) , 943-951
Open AccessDetection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve the prognosis of hormone receptor-positive HER2-negative advanced/metastatic breast cancer (HR+/HER2− mBC). However, some cancers show resistance to CDK4/6i and have a poor prognosis. The non-luminal disease score (NOLUS) was developed to predict non-luminal disease using immunohistochemical analysis. Methods: The association between the efficacy of CDK4/6i and NOLUS was investigated by evaluating pathological and clinical data, including real-world progression-free survival (rw-PFS) and overall survival (OS). Real-world data of patients with HR+/HER2− mBC who received CDK4/6i therapy [palbociclib or abemaciclib] as first- or second-line endocrine treatments was obtained. NOLUS was calculated using the formula: NOLUS (0–100) = − 0.45 × estrogen receptor (ER) (%) − 0.28 × progesterone receptor (PR) (%) + 0.27 × Ki67(%) + 73, and the patients were divided into two groups: NOLUS-positive (≥ 51.38) and NOLUS-negative (< 51.38). Results: Of the 300 patients, 28 (9.3%) were NOLUS-positive, and 272 (90.7%) were NOLUS-negative. The expression rates (%) of ER and PgR in NOLUS-positive patients were lower than those in NOLUS-negative patients (p < 0.001). Ki67 expression was higher in NOLUS-positive patients. There were statistically significant differences in prognosis (rw-PFS and OS) between the two groups. Moreover, NOLUS-negative patients showed statistically better rw-PFS with first-line therapy than second-line therapy. However, NOLUS-positive patients showed poor prognoses with both the first and second therapeutic lines, suggesting CDK4/6i inefficacy for NOLUS-positive patients. Conclusions: The efficacy and prognosis of CDK4/6i significantly differed between the NOLUS-positive and NOLUS-negative patients. This feasible method can predict patients with HR+/HER2− mBC resistant to CDK4/6i and help select a better therapeutic approach to overcome resistance.